The available data from preclinical and pharmacological studies on the role of the C-O-methyl transferase (COMT) support the hypothesis that abnormal catecholamine transmission has been implicated in the pathogenesis of mood disorders (MD). We examined the relationship of a common functional polymorphism (Val108/158Met) in the COMT gene, which accounts for four-fold variation in enzyme activity, with 'early-onset' (EO) forms (less than or equal to 25 years) of MD, including patients with major depressive disorder (EO-MDD) and bipolar patients (EO-BPD), in a European multicenter case-control sample. Our sample includes 378 MDD (120 EO-MDD), 506 BPD (222 EO-BPD) and 628 controls. An association was found between the high-activity COMT Val allele, particularly the COMT Val/Val genotype and EO-MDD. These findings suggest that the COMT Val/Val genotype may be involved in EO-MDD or may be in linkage disequilibrium with a different causative polymorphism in the vicinity. The COMT gene may have complex and pleiotropic effects on susceptibility and symptomatology of neuropsychiatric disorders. Molecular Psychiatry (2005) 10, 598-605.
Mood disorders (MD), including bipolar disorder (BPD) and major depressive disorder (MDD), are multifactorial diseases, presumed to have a complex inheritance, involving the interaction of various genes in combination with environmental factors. A polygenic origin implies a limited impact of each gene and a high phenotypic heterogeneity of the disorder, and/ or a large impact in a small number of families. Association studies are appropriate for searching susceptibility genes with minor effects involved in MD, 1 but large samples of subjects are necessary to obtain sufficient power of detection. Conflicting results in molecular genetic studies of MD may be due to the clinical and genetic heterogeneity of the disorder. Thus, attention is shifting towards clinical indicators of MD, which may be able to identify more heritable subforms of the disease. Evidence is accumulating from ascendant and descendant family studies, that 'early onset' (EO) forms of MD may be associated with greater familial risk to relatives. [2] [3] [4] [5] Furthermore, a recent study showed the existence of intrafamilial correlation for age at onset in BPD. 4 Finally, EO was reported to be involved in anticipation (increase in disease severity and decrease in age at onset in succeeding generations), as suggested in BPDs. [6] [7] [8] [9] EO of MD could be an important variable in identifying some forms of MD that are more genetically homogeneous or may carry some degree of relatively increased genetic loading or phenotypic expression. 5 EO, as a specific phenotype, may be helpful to identify vulnerability genes (ie increase penetrance). Age at onset (AAO) of the disease has been found to be a key indicator for a more heritable form of MD, in delineating disorder subtypes, thus leading to gene identification (in other neuropsychiatric disorders, as is the case in Alzheimer's disease). 10 A clinical study reported an association of BPD in a group of subjects with the velocardiofacial syndrome (VCFS), a congenital disorder that presents with a constellation of symptoms, such as cleft palate, cardiac problems, facial abnormalities, and learning disabilities. 11 Within these subjects, 64% met DSM-III-R criteria for a spectrum of BPD with full syndromal onset in late childhood or early adolescence. These findings support a strong association between VCFS and early-onset BPD. 11 On a molecular level, the disorder has been linked to a hemizygous interstitial deletion of chromosome 22q11, which may involve the gene coding for the catechol O-methyl transferase (COMT), a methylation enzyme, which catalyzes endogenous catecholamines (eg, dopamine, epinephrine, norepinephrine) by O-methylation in the presence of S-adenosylmethionine and magnesium ions. 12 The COMT gene, considered as a possible 'candidate gene' for MD, was characterized and sequenced. [13] [14] [15] There are two common variants, a low-and a high-activity form, due to a G-to-A transition at codon 158, predicting an amino-acid change (Val  158 Met) . 12, 16, 17 The enzyme containing Met is unstable at 371C and has 1 4 of the activity of the enzyme containing Val. 12 The alleles are codominant, as heterozygous individuals have enzyme activities that are midway between that of homozygous individuals. The erythrocyte COMT activity has been shown to be higher in BPD patients than their individually matched controls, and to be increased by 60% in female MDD patients compared to female controls, with a significantly higher enzyme activity than in the corresponding male patients. 18 Moreover, the COMT activity was reported to be highest at an early age (in particular from age 6 to 20) and lowest after age 50 years. 19 A relationship between COMT Met activity and BPD was postulated as a mechanism for the BPD phenotype in cases of comorbid BPD and VCFS. 20 Some studies have reported a positive association between the low-activity COMT Met allele and MDD, 21 BPD, [22] [23] [24] BPD with rapid cycling, 25 and BPD with ultradian rapid cycling (48 h cycles). 20 However, several case-control association studies of COMT alleles have been negative (see Table 2 ). Linkage studies have supported a locus for both schizophrenia 26 and BPD 27,28 on chromosome 22q, near the location of VCFS.
In the present study, we examined the relationship of the functional COMT (Val 158 Met) polymorphism in the EO subphenotype of MD, in a European multicenter association study, using a case-control design in samples of BPD, MDD, and control subjects.
Materials and methods

Subjects
The present sample was recruited within the Biomedical European Collaborative Study on Molecular Genetics in Affective disorders (BIOMED 2, Contract No. BMH4-CT-97-2307). This network was established and supported within the framework of the European Commission. The objectives and detailed methodology of the project were described previously. 29 A total of six clinical centers participated in the present study (Athens, Bonn, Brussels, Edinburgh, Milan, Sofia, see Table 1 ). All centers used DSM-III-R and DSM-IV classification systems criteria for categorical diagnoses (BPD and MDD) based on specific criteria, assessed by standardized interviews that have shown reliability. All subjects were interviewed by experienced psychiatrists fluent in English as well as in the language of the population being studied, using the Schedule for Affective Disorders and Schizophrenia-Lifetime Version 30 and the Schedule for Clinical Assessment of Neuropsychiatry. 31 One of the two diagnostic interviews was used for all patients and all controls recruited for the project. The decision to adopt two instruments arose out of different research experience within individual research teams. Data published by the European Science Foundation ESF showed good concordance between the two instruments. 32 Other sources such as hospital case notes were also include to make diagnoses. A total of 1512 subjects were selected with DNA and clinical data: 378 MDD subjects (129 males and 249 females), including 120 with early onset (r25 years, named EO-MDD), 506 BPD subjects (217 males and 288 females), including 222 with early onset (r25 years, named EO-BPD), and 628 controls (316 males and 312 females). To limit ethnogeographic stratification biases, samples were performed within centers with subjects ethnically homogenous. The age distribution between MDD and BPD patients is described in Figure 1 . The age cutoff of 25 (r25) for early onset (EO) was chosen according to a recent report that showed three age-at-onset subgroups of BPD patients (mean ages at onset were 17 years, 25 years, including 50% of patients, and 40 years, respectively), having different familial vulnerability factors. 33 In our sample, 49.2% of BPD and 33.5% of MDD patients had EO. AAO was defined as the 'age at which the patient first met the DSM criteria for major depressive/(hypo)manic episode'. To test alternative approaches based on phenotypic traits, we selected clinical subgroups, characterized by a positive family history of MD in first-degree relatives (n ¼ 166 BPD; n ¼ 107 MDD), history of suicidal attempt (SA) (n ¼ 126 BPD, n ¼ 83 MDD), presence of psychotic features (delusions or hallucinations, n ¼ 157 BPD, n ¼ 29 MDD) and presence of rapid cycling (RC) in BPD (n ¼ 21 RC, 220 without RC). Family data were assessed using the Family History RDC instrument. 34 When available, family data were also collected from relatives. Positive family history was defined as having at least one first-degree relative affected with BPD or MDD. Subjects for whom clinical information to categorize them into those subgroups was not available were not included in these analyses. For the control group, subjects with a positive personal or familial history of psychiatric disorder were excluded. Local medical and research ethics committees approved the study and informed consent was obtained from patients and controls.
Genotyping
The COMT gene, located at 22q11.2, has six exons and two promoters. The COMT (Val 158 Met) polymorphism is due to a G-to-A transition at codon 158 of the COMT gene, resulting in a valine-to-methionine substitution. 16 The two alleles are commonly referred to as COMT Val and COMT Met. Genomic DNA was extracted from whole blood by NaCl precipitation. 35 PCR was performed with the following primers: 5 0 -ACT GTG GCT ACT CAG CTG TG-3 0 and 5 0 -CCT TTT TCC AGG TCT GAC AA-3 0 . The PCR was carried out in a 10-ml volume containing 20 ng of genomic DNA, 10 pmol of each primer, 200 mM of each dNTP, 1 Â PCR Gold Buffer (Applied Biosystem), and 0.025 U/ml of Taq Gold Polymerase (Applied Biosystem). After an initial denaturation step of 5 min at 961C, 35 cycles of amplification (45 s at 961C, 45 s at 601C, and 45 s at 721C) and a final extension step of 10 min at 721C were performed. An aliquot of PCR product was digested using NlaIII (New England BioLabs); fragments were separated in 4% agarose gels. Depending on the presence or absence of the restriction NlaIII site, either one fragment (allele COMT Val) or two fragments (allele COMT Met) were produced ( Table 2) .
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) was tested separately in the three groups (MDD, BPD, and controls), by using the exact HW test and the GENEPOP, 3.d program-updated version of GENE-POP. 36 In order to determine whether there is an association of COMT and MD, we performed logistic regression analyses. We evaluated the effect of genotypes and alleles as predictors of the dependant variable (the diagnosis status). Results of these analyses are shown in Table 3 . To evaluate the possible confounding and/or modifying effect of center and gender, stratified analyses were performed and odds ratios (OR) and confidence intervals (95% CI) were calculated. The Mantel-Haenszel test 37 was applied to evaluate the possible confounding effect of gender/center. The Breslow-Day 38 test was applied to test the homogeneity of the stratum-specific estimates (center and gender for strata and presence of genotype COMT Val/Val as exposition).
Results
No significant deviation from HWE was observed in any of the three groups. between MDD cases and control subjects (see Table  3a ). No association emerged when considering subphenotypes including MDD patients with history of SA, presence of psychotic features, and positive family history (results not shown). Table 3f ).
COMT (Val
For each comparison, Mantel-Haenzsel and Breslow-Day tests were carried out to eliminate a confounding and a modifier effect. Differences between OR crude and OR MH estimated according to the Mantel-Haenzsel test never exceed 15%, excluding confounding effects of gender and center. The Breslow-Day tests were nonsignificant, excluding gender and center modifier effect.
Discussion
In this multicentric European study, an association was found in favor of the high-activity Val allele of the common functional COMT (Val 158 Met) polymorphism, in EO-MDD patients. These findings indicate that the COMT Val allele and especially the COMT Val/Val genotype may represent a modifying gene that predisposes to early onset in MDD patients or reflect linkage disequilibrium with a different causative polymorphism in the vicinity. A previous report showed that homozygosity for the high-activity COMT Val/Val genotype is associated with a 3-4-fold increase of COMT enzyme activity compared with homozygotes for the low-activity variant. 12 Individuals with COMT Val/Val genotype would be expected to have lower levels of transynaptic catecholamines due to an increased COMT degradation of norepinephrine and dopamine. Age-specific variations in neurotransmitters and other developmental differences may support different phenotypic manifestations of MDD across the age span. Another way to substantiate our findings should be to assess cathecolamine metabolites in the CSF as endophenotype. AAO and the intrafamilial correlation for AAO may be attributable to different genetic vulnerability factors/or the same genetic mechanism differently expressed in various environments at developmental steps. Other results have shown in genetic association studies on subgroups of AAO-BPD an association between a marker of the tyrosine hydroxylase gene and late onset of BPD, and an association between the apolipoprotein E gene and early onset of BPD, 33, 39 while it has been suggested that EO in MD is the most severe form (particularly for BPD), associated with higher rate of comorbidity, poor response to antidepressants and poor prognosis. The COMT Val variant, as a risk factor of EO-MDD, could help to differentiate EO-MDD and EO-BPD in young patients with major depression and better define a therapeutic strategy. However, it is important to recognize that this candidate gene variant may also influence susceptibility to other psychiatric conditions. This gene variant may give rise to multiple physiological abnormalities that separately contribute to other diseases, or it may produce a single deficit that is common to these disorders. The same polymorphism has been shown to affect executive function and the physiology of the prefrontal cortex in humans, probably by affecting prefrontal dopamine signalling. The COMT Val allele, associated with relatively poor prefrontal function, may increase the risk for schizophrenia. 40 COMT resides on chromosome 22q, which showed significant genome-wide linkage for both schizophrenia and BPD in a recent meta-analysis, further supporting a common effect of this polymorphism in both disorders. 41 COMT may have complex and pleiotropic effects on the susceptibility and symptomatology of neuropsychiatric disorders. We could also hypothesize an indirect effect of COMT polymorphism on EO-MDD if we consider the personality trait of neuroticism, a normally distributed quantitative trait, highly genetically correlated with anxiety and depression, that may be a vulnerability to either type of disorder: A recent study reported a weak evidence for association with the same functional COMT polymorphism. 42 Our results are not in line with some previous association studies (see Table 2 ). Conflicting results may be explained by multiple reasons: type one and two errors, recruitment bias, and phenotypic and genetic heterogeneity. Samples used in previous studies did not have a sufficient statistical power for detecting association, if we consider a minor or moderate effect of genetic variant at this polymorphism. There are also limitations of our study: Assessment of AAO was retrospective and thus subject to recall error. Several confounding factors may have influenced the evaluation of AAO (retrospective data: common bias in patients who are interviewed at a later age and have no living parents who can provide valid information on AAO). As reported in a the recent meta-analysis of case-control and family-based studies, 43 the frequency of the COMT Val allele varies widely across European populations, ranging from 42 to 60%. In spite of the fact that we did not detect center effect in genotype distributions, a stratification bias due to ethnic differences cannot be excluded, as it was reported for this polymorphism. 43 Though the association between the COMT Val allele and BPD with history of SA did not resist to multiple test correction, these findings have to be taken into consideration, according to a recent study supporting the hypothesis that the same COMT polymorphism may modify the phenotype of suicide attempts and anger-related traits. 44 So, it should warrant further investigation to clarify this issue. Consequently, we suggest to further investigate COMT in other populations, using family-based association methods (less susceptible than case-control association design to inferential errors based on ethnic stratification bias), to further explore the genetics of EO-MDD and history of SA.
